Heart
Heart disease is a leading cause of death across the world. However, there are only a few ongoing clinical trials. One of the main challenges is the use of traditional testing models. Our differentiation method allows us to generate high quality and high purity cardiomyocytes that target the need for better alternative models.
We offer differentiated cardiomyocytes from our biobank. However, we can also reprogram patient-derived samples.
Our iPSC-CMs have multiple applications, such as in vitro drug metabolism studies, safety screening in drug discovery, toxicology studies, and cellular therapy development.
Many non-ischemic cardiomyopathies are caused by genetic mutations that affect cellular ion channels and heart contraction.
Stemnovate offers iPSC-CMs to model disease. We offer an ideal model for better identification and management of cardiology patients susceptible to sudden cardiac death, drug screening and research.
Our cardiomyocytes generated from iPSCs offer an alternative to in vivo animal testing. We are committed to reducing the use of animals in research.
We help overcome the challenge of treating congenital disease (genetic variants pathogenicity).
Our patient-derived iPSC cardiomyocytes allow researchers to understand disease mechanisms at a personalised level.
We offer an ideal model for better identification and management of cardiology patients susceptible to sudden cardiac death.